GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IO Biotech Inc (NAS:IOBT) » Definitions » Price-to-Owner-Earnings

IO Biotech (IO Biotech) Price-to-Owner-Earnings : (As of Jun. 06, 2024)


View and export this data going back to 2021. Start your Free Trial

What is IO Biotech Price-to-Owner-Earnings?

As of today (2024-06-06), IO Biotech's share price is $1.26. IO Biotech does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for IO Biotech's Price-to-Owner-Earnings or its related term are showing as below:


IOBT's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 33.81
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-06-06), IO Biotech's share price is $1.26. IO Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.87. Therefore, IO Biotech's PE Ratio for today is At Loss.

As of today (2024-06-06), IO Biotech's share price is $1.26. IO Biotech's EPS without NRI for the trailing twelve months (TTM) ended in was $-1.86. Therefore, IO Biotech's PE Ratio without NRI for today is At Loss.


IO Biotech Price-to-Owner-Earnings Historical Data

The historical data trend for IO Biotech's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IO Biotech Price-to-Owner-Earnings Chart

IO Biotech Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
- - - - -

IO Biotech Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of IO Biotech's Price-to-Owner-Earnings

For the Biotechnology subindustry, IO Biotech's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IO Biotech's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IO Biotech's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where IO Biotech's Price-to-Owner-Earnings falls into.



IO Biotech Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

IO Biotech's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=1.26/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


IO Biotech  (NAS:IOBT) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


IO Biotech Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of IO Biotech's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


IO Biotech (IO Biotech) Business Description

Traded in Other Exchanges
N/A
Address
Ole Maaloes Vej 3, Copenhagen N, DNK, DK-2200
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.
Executives
Brian Burkavage officer: Chief Accounting Officer C/O PASSAGE BIO, INC., ONE COMMERCE SQUARE, 39TH FLOOR, PHILADELPHIA PA 19103
Heidi Hunter director C/O SUTRO BIOPHARMA, INC., 310 UTAH AVE., SUITE 150, SOUTH SAN FRANCISCO CA 94080
Partners Kurma 10 percent owner 24 RUE ROYALE, PARIS I0 75008
Novo Holdings A/s 10 percent owner TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Vivo Opportunity Fund Holdings, L.p. 10 percent owner 192 LYTTON AVENUE, PALO ALTO CA 94301
Devin Whittemore Smith officer: General Counsel C/O MINERVA NEUROSCIENCES, INC., 1601 TRAPELO ROAD, SUITE 286, WALTHAM MA 02451
Vivo Capital Fund Ix, L.p. 10 percent owner 192 LYTTON AVENUE, PALO ALTO CA 94301
Vivo Opportunity, Llc 10 percent owner 192 LYTTON AVENUE, PALO ALTO CA 94301
Qasim Iftikhar Ahmad officer: Chief Medical Officer 1209 ORANGE STREET, WILMINGTON DE 19801
Amy Sullivan officer: Chief Financial Officer 38 OUTLOOK ROAD, SWAMPSCOTT MA 01907
David V Smith director 6035 STONERIDGE DRIVE, PLEASANTON CA 94588
Lundbeckfond Invest A/s 10 percent owner SCHERFIGSVEJ 7, COPENHAGEN G7 DK-2100
Jack Nielsen director C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142
Vanessa Malier director 1209 ORANGE STREET, WILLMINGTON DE 19801
Claus A. Andersson director 1209 ORANGE STREET, WILMINGTON DE 19801